An Open Label Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Children Previously Vaccinated With the Ad26.ZEBOV and MVA-BN-Filo Vaccine Regimen
Latest Information Update: 15 Dec 2023
Price :
$35 *
At a glance
- Drugs Ad26 EBOV vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms EBOVAC Booster Study
- 14 Jul 2022 Status changed from active, no longer recruiting to completed.
- 25 Feb 2022 Planned End Date changed from 30 Nov 2021 to 31 Mar 2022.
- 14 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Sep 2021.